Wegovy's UK Release Date and What's Changed Since

When exactly did Wegovy get approved in the UK?

The MHRA granted Wegovy its UK marketing authorisation in January 2023. That approval covered once-weekly subcutaneous semaglutide injections for adults with a BMI of 30 or above, or 27 or above alongside at least one weight-related health condition. NICE followed in March 2023 with its own recommendation (TA875), endorsing Wegovy for use in specialist weight management services on the NHS, though with a strict two-year treatment limit and the requirement that patients receive multidisciplinary support alongside the medicine.

In practice, NHS prescriptions through specialist services began from around mid-2023, while private prescriptions through regulated online pharmacies became available somewhat earlier, as private prescribers could act as soon as the MHRA licence was in place. The semaglutide approval date marked a genuine shift in how obesity medicine is treated in the UK, the first medicine in this class licensed not for diabetes but purely for weight management.

If you'd like to read more about the medicine itself, our semaglutide overview covers how it works, what to expect and who it may suit.

What happened after that initial launch?

The semaglutide story didn't stand still after January 2023. Supply shortages caused disruption through much of 2023 and 2024, as global demand outpaced manufacturing capacity. Novo Nordisk worked to scale production, and UK availability improved significantly through 2025.

Then, on 14 April 2026, the MHRA approved a higher 7.2mg maintenance dose of Wegovy, delivered via a dedicated single-dose pen, one pre-set injection per week, with a built-in covered needle that locks after use. Clinical trial data for this dose reported around 20.7% average weight loss over 72 weeks, narrowing the gap with tirzepatide at its highest licensed dose. It's worth noting the 7.2mg pen is licensed for BMI of 30 or above only; it is not approved for the cardiovascular risk-reduction indication. The titration schedule still begins at 0.25mg, rising every four weeks or so under prescriber guidance, with 7.2mg as the ceiling.

For more on where Wegovy can be obtained now that the medicine is established in the market, the Wegovy: where to buy page explains the legitimate routes clearly.

Has semaglutide received any other UK approvals since its weight-loss launch?

Yes, two further ones. First, semaglutide already held a licence for reducing the risk of serious cardiovascular events in eligible adults with obesity and established heart disease, a separate indication from weight management. Second, on 3 July 2026, the MHRA granted a conditional approval for Wegovy to treat MASH (metabolic dysfunction-associated steatohepatitis), a form of fatty liver disease with moderate-to-advanced fibrosis in adults. This is a significant expansion: it makes Wegovy one of very few medicines with a licensed indication for this condition. Both of these indications are distinct from weight management, and our Wegovy page covers the full picture of what's licensed and for whom.

The most recent milestone (as of summer 2026) is the approval of Wegovy tablets, an oral formulation of semaglutide that reached the UK market in June 2026. The MHRA approved it on 11 June 2026 as the first oral GLP-1 medicine licensed for weight loss in the UK, ahead of any other European country. The tablet is taken once daily, first thing in the morning before food or drink, and escalates from 1.5mg up to a 25mg maintenance dose. For patients who prefer not to inject, that approval matters.

You can read about how long semaglutide remains usable once you have your pen or tablet pack, a practical question our prescribers hear regularly.

Why does the NHS access timeline feel so different from private availability?

This is the bit that frustrates a lot of people, and honestly, understandably so. The MHRA licence and the NICE recommendation happened quickly in 2023. But NICE's TA875 recommendation ties NHS Wegovy access to specialist weight management services with multidisciplinary support, not GP surgeries, not general outpatient referrals. Those services have limited capacity and often carry long waiting lists.

Private prescribing fills that gap for people who don't want to wait or who don't yet meet the NHS's criteria. A regulated online pharmacy with a GPhC-registered prescriber can assess and, if you're clinically suitable, prescribe Wegovy without a referral. That said, a proper clinical assessment is still required, the prescription-only status of these medicines means no legitimate service will dispense them without one.

If cost is part of your thinking, the weight-loss treatment overview sets out the private routes and what's typically included in the price. And if you'd like to understand who reviews consultations at nume specifically, our clinical team page explains the approach. When you're ready to find out whether Wegovy is right for you, speak to our prescribers via a free consultation, reviewed the same day by a real clinician, not a queue.